{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:49:43Z","timestamp":1791244183861,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515011769"],"award-info":[{"award-number":["2025A1515011769"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010448"],"award-info":[{"award-number":["2025A1515010448"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515140117"],"award-info":[{"award-number":["2023A1515140117"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022B1515120043"],"award-info":[{"award-number":["2022B1515120043"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["HZZD202402"],"award-info":[{"award-number":["HZZD202402"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["202201020335"],"award-info":[{"award-number":["202201020335"]}],"id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017369","name":"Scientific and Technological Planning Project of Guangzhou City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["2023VPPC-R08"],"award-info":[{"award-number":["2023VPPC-R08"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["2023YFE0118700"],"award-info":[{"award-number":["2023YFE0118700"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92374203"],"award-info":[{"award-number":["92374203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741379"],"award-info":[{"award-number":["2023M741379"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023TQ0136"],"award-info":[{"award-number":["2023TQ0136"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences &amp; Peking Union Medical College","doi-asserted-by":"publisher","award":["2024-JKCS-08"],"award-info":[{"award-number":["2024-JKCS-08"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116339","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:33:45Z","timestamp":1770482025000},"page":"116339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting hepatocellular carcinoma with MAGE-A3-specific TCR-engineered T cells: A therapeutic approach"],"prefix":"10.1016","volume":"173","author":[{"given":"Yun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.116339_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2026.116339_bb0010","first-page":"54","article-title":"Progress and prospects of biomarkers in primary liver cancer (review)","volume":"57","author":"Gao","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0015","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4254\/wjh.v9.i6.300","article-title":"Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma","volume":"9","author":"Gera","year":"2017","journal-title":"World J. Hepatol."},{"issue":"13","key":"10.1016\/j.intimp.2026.116339_bb0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116339_bb0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jhep.2025.07.033","article-title":"Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma","volume":"84","author":"Meyer","year":"2026","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.intimp.2026.116339_bb0035","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116339_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/imt.15.29","article-title":"MAGE-A3: an immunogenic target used in clinical practice","volume":"7","author":"Esfandiary","year":"2015","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2026.116339_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/1750743X.1.1.19","article-title":"MAGE A3 antigen-specific cancer immunotherapeutic","volume":"1","author":"Peled","year":"2009","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.intimp.2026.116339_bb0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14712598.2014.880421","article-title":"Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer","volume":"14","author":"Adam","year":"2014","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2026.116339_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S35570","article-title":"Cancer testis antigen and immunotherapy","volume":"2","author":"Krishnadas","year":"2013","journal-title":"Immunotargets Ther"},{"issue":"5","key":"10.1016\/j.intimp.2026.116339_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050677","article-title":"MAGE-A3 is a clinically relevant target in undifferentiated pleomorphic sarcoma\/myxofibrosarcoma","volume":"11","author":"Conley","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apm.13132","article-title":"Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer","volume":"129","author":"Khalvandi","year":"2021","journal-title":"Apmis"},{"issue":"3","key":"10.1016\/j.intimp.2026.116339_bb0075","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3892\/ol.2017.5665","article-title":"Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer","volume":"13","author":"Chen","year":"2017","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2026.116339_bb0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamasurg.2013.4113","article-title":"MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine","volume":"149","author":"Batchu","year":"2014","journal-title":"JAMA Surg."},{"issue":"2","key":"10.1016\/j.intimp.2026.116339_bb0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13402-015-0261-5","article-title":"Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer","volume":"39","author":"Xie","year":"2016","journal-title":"Cell. Oncol. (Dordr)"},{"issue":"11","key":"10.1016\/j.intimp.2026.116339_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241551","article-title":"MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0095","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1155\/2013\/907394","article-title":"Combined analysis of serum alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in peripheral blood for diagnosis of hepatocellular carcinoma","volume":"35","author":"Cui","year":"2013","journal-title":"Dis. Markers"},{"issue":"10","key":"10.1016\/j.intimp.2026.116339_bb0100","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/JTO.0000000000000653","article-title":"Safety and immunogenicity of MAGE-A3 Cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell lung Cancer","volume":"10","author":"Pujol","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009589","article-title":"Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2021","journal-title":"PLoS Genet."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0110","first-page":"6998","article-title":"Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: a case report","volume":"16","author":"Xia","year":"2018","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0115","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol. Int."},{"issue":"4","key":"10.1016\/j.intimp.2026.116339_bb0120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s12072-023-10524-x","article-title":"Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol. Int."},{"issue":"13","key":"10.1016\/j.intimp.2026.116339_bb0125","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.7150\/thno.84710","article-title":"Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.intimp.2026.116339_bb0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1399-0039.1994.tb02394.x","article-title":"HLA class I alleles of LCL 721 and 174 x CEM.T2 (T2)","volume":"44","author":"Steinle","year":"1994","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.intimp.2026.116339_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100789","article-title":"Optimization of antigen-specific CD8(+) T cell activation conditions for infectious diseases including COVID-19","volume":"2","author":"Xiao","year":"2021","journal-title":"STAR Protoc"},{"issue":"9","key":"10.1016\/j.intimp.2026.116339_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139485","article-title":"High-resolution analyses of human leukocyte antigens allele and haplotype frequencies based on 169,995 volunteers from the China bone marrow donor registry program","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2026.116339_bb0145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116339_bb0150","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/carcin\/bgac073","article-title":"GFPT1 promotes the proliferation of cervical cancer via regulating the ubiquitination and degradation of PTEN","volume":"43","author":"Li","year":"2022","journal-title":"Carcinogenesis"},{"issue":"12","key":"10.1016\/j.intimp.2026.116339_bb0155","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1373\/clinchem.2005.051532","article-title":"Enzyme immunoassay (EIA)\/enzyme-linked immunosorbent assay (ELISA)","volume":"51","author":"Lequin","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.intimp.2026.116339_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114700","article-title":"Oncogenic activity and cellular functionality of melanoma associated antigen A3","volume":"192","author":"Sch\u00e4fer","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116339_bb0165","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N","article-title":"Expression of MAGE-antigens in normal tissues and cancer","volume":"85","author":"Jungbluth","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116339_bb0170","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.intimp.2026.116339_bb0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41422-025-01077-9","article-title":"TCR catch bonds nonlinearly control CD8 cooperation to shape T cell specificity","volume":"35","author":"Qin","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2026.116339_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.iotech.2019.06.003","article-title":"T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation","volume":"2","author":"Bentzen","year":"2019","journal-title":"Immunooncol Technol"},{"issue":"2","key":"10.1016\/j.intimp.2026.116339_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.intimp.2026.116339_bb0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"6589","key":"10.1016\/j.intimp.2026.116339_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl5282","article-title":"Tuning T cell receptor sensitivity through catch bond engineering","volume":"376","author":"Zhao","year":"2022","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2026.116339_bb0200","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116339_bb0205","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nri911","article-title":"Functional significance of the perforin\/granzyme cell death pathway","volume":"2","author":"Trapani","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116339_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:56:08Z","timestamp":1778820968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"alternative-id":["S1567576926001839"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116339","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting hepatocellular carcinoma with MAGE-A3-specific TCR-engineered T cells: A therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116339"}}